Fig. 4
From: Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist
PD Marker Investigation and IL17A Kinetics in Disease Progression. a Plasma IL6 concentration on day 5 of experiment, 24 h after IMQ application of previous day (n = 6). b 24-h kinetical change of plasma IL17A and IL6 on day 5 of experiment after 42 mg IMQ application (n = 4). c Plasma IL6 concentration on day 5 of experiment, 2.5 h after IMQ application (n = 6). d Kinetical change of plasma IL6 for each group, 0–6 h after IMQ application on day 5 of experiment (n = 4). e Plasma IL6 concentration on day 5 of experiment, 0.5 h after IMQ application. f Time course of inflammatory signaling activation on day 5 of modelling. Data was expressed as mean ± SEM *P < 0.05, **P < 0.01 comparing to model group